Fasenra Pediatric Japan Post-Marketing Study(PMS)

Conditions: Bronchial Asthma

Sex: All

Healthy volunteers: No

Enrollment: 40

Sponsor: AstraZeneca

Location: Research Site Aichi

Summary

The purpose of the investigation is to confirm the followings under the post-marketing actual use of Fasenra® Subcutaneous Injection 30 mg / 10mg Syringe (hereinafter referred to as Fasenra). 1. Development of unexpected related AEs\* 2. To grasp development of related AEs\* in the real-world post-marketing setting. 3. Effectiveness (pulmonary function and asthma control) \* AEs investigator or MAH considers that there is a reasonable possibility that the experience may have been caused by the drug

Eligibility Criteria

Inclusion Criteria: The evaluable patients in children aged ≥6 years to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06427876). StuddyBuddy aggregates publicly available trial information.